These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 38751545)
21. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. Wander SA; Han HS; Zangardi ML; Niemierko A; Mariotti V; Kim LSL; Xi J; Pandey A; Dunne S; Nasrazadani A; Kambadakone A; Stein C; Lloyd MR; Yuen M; Spring LM; Juric D; Kuter I; Sanidas I; Moy B; Mulvey T; Vidula N; Dyson NJ; Ellisen LW; Isakoff S; Wagle N; Brufsky A; Kalinsky K; Ma CX; O'Shaughnessy J; Bardia A J Natl Compr Canc Netw; 2021 Mar; ():1-8. PubMed ID: 33761455 [TBL] [Abstract][Full Text] [Related]
22. Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Orozco Leal G; Armstrong N; Kernohan A; Ahmadu C; Coughlan D; McDermott K; Duffy S; O'Meara S; Robinson T; Vale L; Kleijnen J Pharmacoeconomics; 2023 Jul; 41(7):741-750. PubMed ID: 36952138 [TBL] [Abstract][Full Text] [Related]
23. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer. Goetz MP; Martin M; Tokunaga E; Park IH; Huober J; Toi M; Stoffregen C; Shekarriz S; Andre V; Gainford MC; Price GL; Johnston S Oncologist; 2020 Sep; 25(9):e1346-e1354. PubMed ID: 32536013 [TBL] [Abstract][Full Text] [Related]
24. Role of abemaciclib in primary breast cancer: a narrative review of MonarchE. Takahashi N; Shimizu C; Shimomura A; Toi M Transl Breast Cancer Res; 2022; 3():3. PubMed ID: 38751527 [TBL] [Abstract][Full Text] [Related]
25. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer. Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562 [TBL] [Abstract][Full Text] [Related]
26. Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation. Torres-Guzmán R; Ganado MP; Mur C; Marugan C; Baquero C; Yang Y; Zeng Y; Bian H; Du J; de Dios A; Puig O; Lallena MJ Oncotarget; 2022; 13():864-875. PubMed ID: 35813283 [TBL] [Abstract][Full Text] [Related]
27. Updated Review Article: Cyclin-Dependent Kinase 4/6 Inhibitor Impact, FDA Approval, and Resistance Pathways. Hunter RJ; Park J; Asprer KJ; Doan AH J Pharm Technol; 2023 Dec; 39(6):298-308. PubMed ID: 37974598 [No Abstract] [Full Text] [Related]
28. Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study. D'Angelo A; Giudici F; Chapman R; Darlow J; Kilili H; Sobhani N; Cinelli M; Cappelletti MR; Strina C; Milani M; Generali D Curr Issues Mol Biol; 2022 Sep; 44(9):4255-4267. PubMed ID: 36135204 [TBL] [Abstract][Full Text] [Related]
29. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer. Martin M; Garcia-Saenz JA; Manso L; Llombart A; Cassinello A; Atienza M; Ringeisen F; Ciruelos E Future Oncol; 2020 Nov; 16(33):2763-2778. PubMed ID: 32781837 [TBL] [Abstract][Full Text] [Related]
30. Quality of life with ribociclib Rugo HS; Harmer V; O'Shaughnessy J; Jhaveri K; Tolaney SM; Cardoso F; Bardia A; Maheshwari VK; Tripathi S; Haftchenary S; Pathak P; Fasching PA Ther Adv Med Oncol; 2023; 15():17588359231152843. PubMed ID: 36861085 [TBL] [Abstract][Full Text] [Related]
31. Efficacy, safety and toxicity management of adjuvant abemaciclib in early stage HR+/HER2- high-risk breast cancer. Sammons S; Moore H; Cushman J; Hamilton E Expert Rev Anticancer Ther; 2022 Aug; 22(8):805-814. PubMed ID: 35737886 [TBL] [Abstract][Full Text] [Related]
32. [Pharmacological Effects of CDK4 & 6 Selective Inhibitor Abemaciclib in Hormone Receptor-Positive Breast Cancer]. Tamaki C; Hayashi S; Sato A; Maeda K; Sakaguchi S; Buchanan S; Enatsu S Gan To Kagaku Ryoho; 2019 Sep; 46(9):1405-1411. PubMed ID: 31530780 [TBL] [Abstract][Full Text] [Related]
33. Pharmacoeconomic evaluations of CDK4/6 inhibitors plus endocrine therapy for advanced hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) breast cancer: a systematic review. Zhu L; Wang M; Luo X; Li H; Shan H; Du Q; Zhai Q Ann Transl Med; 2022 Feb; 10(4):233. PubMed ID: 35280368 [TBL] [Abstract][Full Text] [Related]
34. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women. Cersosimo RJ Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120 [TBL] [Abstract][Full Text] [Related]
35. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA. Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662 [TBL] [Abstract][Full Text] [Related]
36. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib. Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118 [TBL] [Abstract][Full Text] [Related]
37. Clinical considerations of CDK4/6 inhibitors in HER2 positive breast cancer. Zhang C; Zhou F; Zou J; Fang Y; Liu Y; Li L; Hou J; Wang G; Wang H; Lai X; Xie L; Jiang J; Yang C; Huang Y; Chen Y; Zhang H; Li Y Front Oncol; 2023; 13():1322078. PubMed ID: 38293701 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer. Paluch-Shimon S; Neven P; Huober J; Cicin I; Goetz MP; Shimizu C; Huang CS; Lueck HJ; Beith J; Tokunaga E; Contreras JR; de Sant'Ana RO; Wei R; Shahir A; Nabinger SC; Forrester T; Johnston SRD; Harbeck N Ther Adv Med Oncol; 2023; 15():17588359231151840. PubMed ID: 36756142 [TBL] [Abstract][Full Text] [Related]
39. Prospective Cohort Study of Combination Therapy With Abemaciclib and Hormonal Therapy for Chemotherapy-Treated Patients With Hormone Receptor-Positive Metastatic Breast Cancer. Miyahara K; Narui K; Uemura Y; Yamada A; Araki K; Fujisawa F; Nakayama T; Ishikawa T; Taira N; Kikawa Y; Aihara T; Mukai H World J Oncol; 2022 Aug; 13(4):216-221. PubMed ID: 36128594 [TBL] [Abstract][Full Text] [Related]
40. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor? Xi J; Ma CX Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]